Publications & Reports

N348I in HIV-1 Reverse Transcriptase Counteracts the Synergy Between Zidovudine and Nevirapine.

Yap SH, Herman BD, Radzio J, Sluis-Cremer N, Tachedjian G
1Retroviral Biology and Antivirals Laboratory, Centre for Virology, Burnet Institute, Melbourne, Victoria, 3004, Australia 2School of Applied Sciences and Engineering, Monash University, Churchill, Victoria, 3842, Australia 3Division of Infectious Disease

Abstract

ABSTRACT:: The efficacy of regimens that include both zidovudine and nevirapine can be explained by the synergistic interactions between these drugs. N348I in HIV-1 reverse transcriptase (RT) confers decreased susceptibility to zidovudine and nevirapine. Here we demonstrate that N348I reverses the synergistic inhibition of HIV-1 by zidovudine and nevirapine. Also, the efficiency of zidovudine-monophosphate excision in the presence of nevirapine is greater for N348I HIV-1 RT compared to the wild-type enzyme. These data help explain the frequent selection of N348I in regimens that contain zidovudine and nevirapine, and suggest that the selection of N348I should be monitored in resource-limited settings where these drugs are routinely used.

Project

Publication

  • Journal: Journal of Acquired Immune Deficiency Syndromes
  • Published: 27/06/2012
  • Volume: 61
  • Issue: 12
  • Pagination: 153-157

Author

Health Issue

Download